A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing

Withdrawn before enrolling · Not applicable

Conditions studied: Sleep Apnea

In brief

This is a single center pilot study evaluating the immediate effects of low-dose acetazolamide on respiratory control in subjects with treatment emergent sleep disordered breathing. The purpose of this study is to assess the immediate effect one-time low-dose acetazolamide on sleep breathing in (Treatment Emergent Sleep Disordered Breathing) TE-CSA subjects compared to subjects' baseline evaluation without acetazolamide. Investigators will also try to determine the immediate effect of one-time low-dose acetazolamide on subjects' resting ventilation and ventilatory response slope compared to subjects' baseline evaluation without acetazolamide.

Key facts

Study ID

NCT02670096

Run by

NYU Langone Health

People needed

0

Starts

2016-01-01

Expected to finish

2017-03-01

Last updated by the study team

2017-01-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 to 80 years
• TE-CSA
• Subjects are capable of giving informed consent

You may not qualify if…

• Hypersensitivity to acetazolamide or other sulfonamides
• Intake of carbonic anhydrase inhibitors within the last 72 hours
• Intake of medication that influences breathing, sleep, arousal or muscle physiology
• Cheyne-Stokes respiration
• Heart failure
• Renal failure
• Liver failure
• Chronic hypercapnea
• Hyponatremia
• Hypokalemia
• Pregnancy
• Breastfeeding mothers
• Active drug/alcohol dependence or abuse history

Where it is running

• New York University School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.